OLD National Bancorp IN Has $445,000 Stock Position in DexCom, Inc. (NASDAQ:DXCM)

OLD National Bancorp IN lowered its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 7.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,584 shares of the medical device company’s stock after selling 301 shares during the period. OLD National Bancorp IN’s holdings in DexCom were worth $445,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. Commerzbank Aktiengesellschaft FI acquired a new position in shares of DexCom during the 4th quarter worth $201,000. CWM LLC raised its holdings in shares of DexCom by 1.4% during the 4th quarter. CWM LLC now owns 148,169 shares of the medical device company’s stock worth $18,386,000 after buying an additional 1,976 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of DexCom by 0.8% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 36,296 shares of the medical device company’s stock worth $4,504,000 after buying an additional 295 shares in the last quarter. Signaturefd LLC raised its holdings in shares of DexCom by 8.4% during the 4th quarter. Signaturefd LLC now owns 9,520 shares of the medical device company’s stock worth $1,181,000 after buying an additional 740 shares in the last quarter. Finally, Powell Investment Advisors LLC acquired a new position in shares of DexCom during the 4th quarter worth $201,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Jereme M. Sylvain sold 3,363 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the transaction, the chief financial officer now owns 71,142 shares in the company, valued at $8,304,405.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now owns 80,441 shares in the company, valued at $10,747,722.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jereme M. Sylvain sold 3,363 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the transaction, the chief financial officer now owns 71,142 shares in the company, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 189,375 shares of company stock worth $25,530,859. Corporate insiders own 0.41% of the company’s stock.

DexCom Stock Up 2.9 %

Shares of NASDAQ:DXCM opened at $137.87 on Thursday. The business’s 50 day simple moving average is $130.58 and its two-hundred day simple moving average is $117.88. The firm has a market cap of $54.60 billion, a P/E ratio of 105.25, a PEG ratio of 2.30 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. DexCom, Inc. has a 52-week low of $74.75 and a 52-week high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.07. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company’s quarterly revenue was up 26.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.34 earnings per share. As a group, research analysts forecast that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Citigroup upped their target price on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Royal Bank of Canada assumed coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price for the company. Raymond James upped their target price on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 23rd. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, UBS Group increased their price target on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $141.40.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.